|
|
Article: Bracco Diagnostics' MultiHance Earns FDA Approval; MRI Imaging Agent Designed for Higher Relaxivity, Enhanced Image Resolution.
- Article from:
- Business Wire
- Article date:
- November 24, 2004
CopyrightCOPYRIGHT 2004 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
PRINCETON, N.J. -- Bracco Diagnostics Inc. today announced that it has received approval from the United States Food & Drug Administration (FDA) to market MultiHance(R) (gadobenate dimeglumine) injection, 529 mg/ml, a gadolinium-based contrast agent for Magnetic Resonance Imaging (MRI). FDA approval of MultiHance expands Bracco Diagnostics' product portfolio within the United States, which includes many leading diagnostic imaging contrast agents.
MultiHance(R) is indicated for use in MRI of the central nervous system in adults to visualize lesions with abnormal blood brain barrier or abnormal vascularity of the brain, spine and associated tissues. Unlike other ...